M&A Deal Summary |
|
|---|---|
| Date | 2018-09-26 |
| Target | GENEWIZ |
| Sector | Life Science |
| Buyer(s) | Azenta |
| Sellers(s) |
Ampersand Capital Partners
OrbiMed Advisors |
| Deal Type | Add-on Acquisition |
| Deal Value | 450M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1978 |
| Sector | Life Science |
| Employees | 3,000 |
| Revenue | 514M USD (2021) |
Azenta is a provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research, and advanced cell therapies for the industry's top pharmaceutical, biotech, academic, and healthcare institutions globally. Azenta was founded in 1978 and is based in Chelmsford, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 18 of 24 |
| Sector (Life Science) | 5 of 7 |
| Type (Add-on Acquisition) | 13 of 19 |
| State (New Jersey) | 1 of 1 |
| Country (United States) | 13 of 15 |
| Year (2018) | 3 of 3 |
| Size (of disclosed) | 3 of 17 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-08-27 |
Brooks Automation - Cryogenic Business
Chelmsford, Massachusetts, United States Brooks Automation, Inc. - Cryogenic Business is a provider of advanced cryo pumps and associated products. Brooks Automation, Inc. - Cryogenic Business is based in Chelmsford, Massachusetts. |
Sell | $675M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-02-11 |
RURO
Frederick, Maryland, United States RURO, Inc. is a software company. RURO develops state of the art computer software for research, biotechnological, pharmaceutical, healthcare and government (homeland security) laboratories in the US and worldwide. RURO, Inc. was founded in 2006 and is based in Frederick, Maryland. |
Buy | $15M |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1988 |
| PE ASSETS | 2.0B USD |
| Size | Large |
| Type | Sector Focused |
Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 37 of 53 |
| Sector (Life Science) | 15 of 24 |
| Type (Add-on Acquisition) | 26 of 38 |
| State (New Jersey) | 5 of 5 |
| Country (United States) | 37 of 50 |
| Year (2018) | 4 of 6 |
| Size (of disclosed) | 3 of 13 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-09-04 |
Nexelis
Laval, Quebec, Canada Nexelis is an immunology-centric CRO specialized in preclinical models and clinical assay development in single and multiplex formats and sample analysis for low-, mid- and large-scale clinical testing. the company's team of scientists and technology platforms have been instrumental in the development, qualification, and validation of assays supporting FDA filings of over 100 new molecular entities, including blockbuster biologics such as vaccines and complex large molecules. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-10-23 |
Genoptix
Carlsbad, California, United States Genoptix, Inc. is one of the largest hematopathology testing laboratories in the U.S., providing thousands of oncologists and pathologists across the United States with comprehensive testing solutions in hematology and solid tumor molecular profiling. Genoptix, Inc. was founded in 1999 and is based in Carlsbad, California. |
Sell | $126M |
| Category | Private Equity Firm |
|---|---|
| Founded | 1989 |
| PE ASSETS | 14.0B USD |
| Size | Large |
| Type | Sector Focused |
OrbiMed Advisors is a global healthcare centric investment firm that invests in medical device, life science, healthcare service, and medical diagnostic companies. OrbiMed maintains three investment disciplines including Public Equity, Private Equity, and Royalty Opportunities. OrbiMed's Public Equity group manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts that invests across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's Private Equity group invests in start-ups through growth equity financings. OrbiMed prefers to be the lead investor and will consider opportunities across North America, Asia, Europe and Israel. OrbiMed's Royalty practice provides commercial-stage healthcare companies with non-dilutive structured debt capital. OrbiMed was formed in 1989 and is based in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 4 |
| Sector (Life Science) | 2 of 3 |
| Type (Add-on Acquisition) | 1 of 1 |
| State (New Jersey) | 1 of 1 |
| Country (United States) | 2 of 3 |
| Year (2018) | 3 of 3 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-06-02 |
Tricida
South San Francisco, California, United States Tricida is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Tricida was founded in 2013 and is based in South San Francisco, California. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-01-30 |
Arcutis
Westlake Village, California, United States Arcutis is focused on developing topical medicines for the treatment of skin diseases. The company’s lead program, ARQ-151, is a topical formulation of roflumilast that is currently in Phase 2 studies for the treatment of plaque psoriasis and atopic dermatitis. The company’s second program, ARQ-250, is a topical JAK1-inhibitor in preclinical development for the treatment of various autoimmune diseases affecting the skin. Arcutis was founded in 2016 and is based in Westlake Village, California. |
Sell | - |
